The rest is here:
Sirona Biochem Corporate Update
Related Post
- Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates - May 10th, 2024
- INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update - May 10th, 2024
- Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights - May 10th, 2024
- Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) - May 10th, 2024
- Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures - May 10th, 2024
- Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - May 10th, 2024
- Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations - May 10th, 2024
- Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates - May 10th, 2024
- Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update - May 10th, 2024
- DBV Technologies to Participate in Upcoming Investor Conferences - May 10th, 2024
- Tempest Reports First Quarter 2024 Financial Results and Provides Business Update - May 10th, 2024
- Theratechnologies Reports on its Annual Meeting of Shareholders - May 10th, 2024
- BioSyent Schedules Q1 2024 Earnings Release for May 16, 2024 - May 10th, 2024
- Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress - May 10th, 2024
- Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress - May 10th, 2024
- vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update - May 10th, 2024
- 23andMe to Report Q4 and Full Year FY2024 Financial Results - May 10th, 2024
- PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer - May 10th, 2024
- Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference - May 10th, 2024
- Inotiv, Inc. Reschedules its Fiscal 2024 Second Quarter Results - May 10th, 2024
- CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach - May 8th, 2024
- Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - May 8th, 2024
- Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - May 8th, 2024
- Aura Biosciences to Participate in Upcoming Investor Conferences - May 8th, 2024
- Krystal Biotech to Present at BofA Securities 2024 Health Care Conference - May 8th, 2024
- Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic... - May 8th, 2024
- Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024 - May 8th, 2024
- Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results - May 8th, 2024
- Immunocore reports first quarter financial results and provides a business update - May 8th, 2024
- Arbor Biotechnologies Announces Acquisition of Serendipity - May 8th, 2024
- Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises... - May 8th, 2024
- Editas Medicine Announces First Quarter 2024 Results and Business Updates - May 8th, 2024
- C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - May 8th, 2024
- OKYO Pharma Announces Participation in May 2024 Investor Conferences - May 8th, 2024
- Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference - May 8th, 2024
- Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference - May 8th, 2024
- PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results - May 8th, 2024
- SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference - May 8th, 2024
- Kymera Therapeutics to Participate in Upcoming May Investor Conferences - May 8th, 2024
- Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - May 8th, 2024
- TAR-210 results show 90 percent recurrence-free survival and 90 percent complete response in patients with high-risk and intermediate-risk... - May 6th, 2024
- Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - May 4th, 2024
- Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List - May 4th, 2024
- Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024 - May 4th, 2024
- 10 Barrel Brewing Introduces Pub Cerveza: a New Twist on ‘Cheap Fun.’ Series - May 4th, 2024
- MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call - May 4th, 2024
- PDS Biotechnology Announces Details of Virtual KOL Event - May 4th, 2024
- Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results - May 4th, 2024
- Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024 - May 4th, 2024
- Ocuphire Pharma to Present at the Aegis Virtual Conference - May 4th, 2024
- Adverum Biotechnologies to Participate in Upcoming May Investor Conferences - May 4th, 2024
- Mithra enters into exclusive negotiations with Gedeon Richter and secures continued funding in the context of its monetization process - May 4th, 2024
- PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy - May 4th, 2024
- Phase 2 data for ERLEADA® ▼(apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localised... - May 4th, 2024
- Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2024 - May 4th, 2024
- TAR-200 monotherapy shows greater than 80 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer - May 4th, 2024
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 4th, 2024
- Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million - May 4th, 2024
- Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting - May 4th, 2024
- electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) - May 4th, 2024
- Compass Pathways to announce first quarter financial results on May 8, 2024 - May 4th, 2024
- Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer - May 2nd, 2024
- Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab - May 2nd, 2024
- Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems - May 2nd, 2024
- Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference - May 2nd, 2024
- Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024 - May 2nd, 2024
- Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024 - May 2nd, 2024
- Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting - May 2nd, 2024
- ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences - May 2nd, 2024
- Coherus to Report First Quarter 2024 Financial Results on May 9, 2024 - May 2nd, 2024
- SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results - May 2nd, 2024
- Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 - May 2nd, 2024
- Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations - May 2nd, 2024
- CARBIOS and Hündgen enter supply agreement for world’s first PET biorecycling plant - May 2nd, 2024
- Ipsen appoints Keira Driansky as EVP, President of North America - May 2nd, 2024
- argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024 - May 2nd, 2024
- Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024 - May 2nd, 2024
- Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024 - May 2nd, 2024
- Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein - May 2nd, 2024
- Iktos announces the appointment of Roman Fleck as Chairman of the Board - May 2nd, 2024
Recent Comments